Salvador F Aliño

Prof. Salvador F Aliño

Department of Pharmacology, University of Valencia, 46010-Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2001 in Journal of Controlled Release
Verified
Journal Article
Closed access
IMInés Moret
Inés Moret
JPJosé Esteban Peris
José Esteban Peris
VGVicent M. Guillem
Vicent M. Guillem
MBMarta Benet
Marta Benet
FRFernando Revert
Fernando Revert
Salvador F AliñoSalvador F Aliño
Salvador F Aliño

9 September 2014 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
LRL Rojas
L Rojas
INI Neumann
I Neumann
MHMaria Jose Herrero
Maria Jose Herrero
VBV Bosó
V Bosó
JRJ Reig
J Reig
Salvador F AliñoSalvador F Aliño
Salvador F Aliño

1 May 2001 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
FDFrancisco Dasí
Francisco Dasí
SLSalvador Lledó
Salvador Lledó
EGEduardo García-Granero
Eduardo García-Granero
RRRoberto Ripoll
Roberto Ripoll
MMMaribel Marugán
Maribel Marugán
Salvador F AliñoSalvador F Aliño
Salvador F Aliño

18 August 2003 in Gene Therapy
Verified
Journal Article
Closed access
PDF file
Salvador F AliñoSalvador F Aliño
Salvador F Aliño
ACA Crespo
A Crespo
FDFrancisco Dasí
Francisco Dasí

24 February 2005 in Gene Therapy
Verified
Journal Article
Open access
PDF file
ACA Crespo
A Crespo
APA Peydró
A Peydró
FDFrancisco Dasí
Francisco Dasí
MBM Benet
M Benet
JCJuan Calvete
Juan Calvete
Salvador F AliñoSalvador F Aliño
Salvador F Aliño
The present study contributes to clarify the mechanism underlying the high efficacy of hepatocyte gene transfer mediated by hydrodynamic injection. Gene transfer experiments were performed employing the hAAT gene, and the efficacy and differential identification in mouse plasma of human transgene versus mouse gene was assessed by ELISA and proteomic procedures, respectively. By applying different experimental strategies such as cumulative dose–response efficacy, hemodynamic changes reflected by venous pressures, intravital microscopy, and morphological changes established by transmission electron microscopy, we found that: (a) cumulative multiple doses of transgene by hydrodynamic injection are efficient and well tolerated, resulting in therapeutic plasma levels of hAAT; (b) hydrodynamic injection mediates a transient inversion of intrahepatic blood flow, with circulatory stasis for a few minutes mainly in pericentral vein sinusoids; (c) transmission electron microscopy shows hydrodynamic injection to promote massive megafluid endocytic vesicles among hepatocytes around the central vein but not in hepatocytes around the periportal vein. We suggest that the mechanism of hydrodynamic liver gene transfer involves transient inversion of intrahepatic flow, sinusoidal blood stasis, and massive fluid endocytic vesicles in pericentral vein hepatocytes.

20 August 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJosé A March-Villalba
José A March-Villalba
JMJosé M Martínez-Jabaloyas
José M Martínez-Jabaloyas
MHMaria Jose Herrero
Maria Jose Herrero
JSJose Santamaria
Jose Santamaria
Salvador F AliñoSalvador F Aliño
Salvador F Aliño
FDFrancisco Dasí
Francisco Dasí
Serum prostate-specific antigen (PSA) is the most widely used marker for diagnosing prostate cancer (PCa). It lacks specificity and predictive value, resulting in inaccurate diagnoses and overtreatment of the disease. The aim of this study was to assess the usefulness of plasma telomerase reverse transcriptase (hTERT) mRNA as a diagnostic and prognostic tool for PCa and its association with clinicopathological parameters of tumors. Plasma hTERT mRNA levels were determined by qRT-PCR in 105 consecutive patients with elevated PSA levels and in 68 healthy volunteers. The diagnostic accuracy, the efficacy as a prognostic factor of biochemical recurrence and the association with tumor clinicopathological parameters of plasma hTERT mRNA and serum PSA tests were determined using univariate and multivariate analyses. The results show that plasma hTERT mRNA is a non-invasive biomarker for PCa diagnosis that shows higher sensitivity (85% vs. 83%), specificity (90% vs. 47%), positive predictive value (83% vs. 56%), and negative predictive value (92% vs. 77%) than serum PSA. Plasma hTERT mRNA is significantly associated with poor prognosis tumor clinicopathological parameters and is a significant independent predictor of PCa (p<0.0001). Univariate analysis identified plasma hTERT mRNA (but not serum PSA) as a significant prognostic factor of biochemical recurrence. Plasma hTERT mRNA Kaplan-Meier curves confirmed the significant differences between groups and patients with higher levels than the cut-off value showed diminished recurrence-free survival (p = 0.004), whereas no differences were observed with serum PSA (p = 0.38). Multivariate analysis indicated that plasma hTERT mRNA (but not serum PSA) and stage were significantly associated with biochemical recurrence. Overall, these findings indicate that hTERT mRNA is a useful non-invasive tumor marker for the molecular diagnosis of PCa, affording a greater diagnostic and prognostic accuracy than the PSA assay and may be of relevance in the follow-up of the disease.